<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="525">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01281293</url>
  </required_header>
  <id_info>
    <org_study_id>Epilepsy (E)-103</org_study_id>
    <secondary_id>E-103</secondary_id>
    <nct_id>NCT01281293</nct_id>
  </id_info>
  <brief_title>Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated</brief_title>
  <acronym>V-COMPAS</acronym>
  <official_title>A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyberonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyberonics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vagus Nerve Stimulation (VNS) Therapy has been approved marked for the treatment of epilepsy
      since 1994. This post-market study is designed to follow the clinical course and outcomes
      for patients with refractory seizures treated with adjunctive VNS Therapy. Seizure
      frequency, seizure severity, side effects burden, depressive symptoms, global impressions,
      and health care utilization will be evaluated. The results of this study will provide data
      to guide physicians and their patients in the use of VNS Therapy for patients with
      refractory seizures who have failed initial trials of anti-epileptic drug (AED) therapy. The
      data being collected is not for the purposes of confirmatory assessment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Minimum ages eligible for the E-103 study is at least 7 years outside of the US, consistent
      with &quot;Non-US&quot; labeling and 12 years for sites in the US.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Two-Year Clinical Follow-up</measure>
    <time_frame>27 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To follow the clinical course of patients with refractory seizures treated with adjunctive VNS Therapy over a two-year follow-up period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy and Safety</measure>
    <time_frame>27 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate over time the efficacy of best medical practice with adjunctive VNS Therapy in patients with refractory seizures.
To evaluate over time the safety and tolerability of best medical practice with adjunctive VNS Therapy in patients with refractory seizures.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Epilepsy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of patients with a diagnosis of refractory seizures that
        are treated with adjunctive VNS Therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients enrolled in the study must meet all of the following criteria at Visit 1:

        (Baseline) if Screening Incl/Excl is omitted:

          1. Patients must agree to be treated with VNS Therapy. The decision to treat with VNS
             Therapy must have been made independent of and prior to participation in the study.

          2. Patients participating at Sites not located in the US must follow the &quot;Non-US&quot;
             labeling and be at least 7 years or older and whose epileptic disorder is dominated
             by partial seizures (with or without secondary generalization) or generalized
             seizures that are refractory to antiepileptic medications; patients participating at
             Sites located in the United States must be 12 years or older and have partial onset
             seizures or must follow the indication for use statement (for VNS Therapy) in the
             country of origin.

          3. Patient and/or caregiver must be able to give accurate seizure counts, health
             outcomes information, and complete study instruments with minimal assistance.

          4. Patient or legal guardian understands study procedures and voluntarily signs an
             informed consent and in the United States a Health Insurance Portability and
             Accountability Act (HIPAA) authorization in accordance with institutional policies.
             In the event that the patient is under the age of 18 the patient will also be
             required to sign an assent affirming their agreement to participate in research
             according to local IRB requirements. Similar authorization is required per EC
             requirements, or equivalent authority.

             Additional Continuation Criteria to be evaluated at Visit 2 (Baseline):

          5. Patient must be taking at least 1 anti-epileptic drug treatment and stable on said
             medications for at least 8 weeks (56 days) prior to baseline. (Rescue medication may
             be allowed on a case-by case basis with Cyberonics approval.)

          6. Patient must have a minimum frequency of 3 seizures (excluding absence seizures,
             simple partial seizures and myoclonic jerks) per month (average over 2 months) prior
             to baseline; maximum frequency is 20 seizures per day.

          7. Patient must have no more than 4 weeks between seizures (over 2 months) prior to
             baseline.

        Exclusion Criteria:

        Patients with any of the following will not be eligible for enrollment:

          1. Patient currently uses, or is expected to use during the study, short-wave diathermy,
             microwave diathermy, or therapeutic ultrasound diathermy.

          2. Patient is expected to require full body magnetic resonance imaging during the
             clinical study.

          3. Patient has a progressive neurological condition (e.g. brain tumor etc.).

          4. In the investigator's opinion, the inability of the patient, legal guardian or
             reluctance of the child to comply with the frequency of clinic visits during the
             treatment phase.

          5. In the investigator's opinion, the patient has a history of noncompliance for seizure
             diary completion.

          6. Patient is currently using an investigational device or pharmacologic medication not
             approved by either EU or US regulatory authority.

          7. Patient has had a previous VNS Therapy implant.

          8. In the investigator's opinion, the patient is suicidal.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Bunker, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Cyberonics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Bunker, PharmD</last_name>
    <phone>281-228-7223</phone>
    <email>Mark.Bunker@cyberonics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Illinois College of Medicine at Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61656-1649</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philidelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Covenant Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Luke's Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurologische Abteilung Krankenhaus Rosenhügel</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>An Verstrepen</last_name>
      <phone>0032 16 34 38 45</phone>
      <email>an.verstrepen@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Lieven Lagae</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epilepsieklinik Tabor - Ladeburger Straße 15</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Steinke, R.N.</last_name>
      <phone>0049+3338 752401</phone>
      <email>m.steinke@epi-tabor.de</email>
    </contact>
    <investigator>
      <last_name>Hans-Beatus Straub</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert-Ludwigs-Universität Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alena Tränkle</last_name>
      <phone>+49 761 270 53660</phone>
      <email>alena.traenkle@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Schulze-Bonhage</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birte Hackelberg</last_name>
      <phone>0049(0)431 597-8519</phone>
      <email>b.hackelberg@neurologie.uni-kiel.de</email>
    </contact>
    <investigator>
      <last_name>Nicolas Lang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Efra Rogowski</last_name>
      <phone>+972 54 4610683</phone>
      <email>efra.rogowski@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Dr. Bruria Ben Zeev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Corbett</last_name>
      <phone>+44 (0) 121 333 8739</phone>
      <email>alison.corbett1@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Bernie Concannon</last_name>
      <phone>+44 (0) 121 333 8739</phone>
      <email>Bernie.Concannon@bch.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Sunny Philip</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foundation Trust Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Hornabrook</last_name>
      <phone>+44 121 371 4821</phone>
      <email>rachel.hornabrook@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Imad Soryal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital Bristol</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Travis</last_name>
      <phone>+44 (0) 117 414 6686</phone>
      <email>samantha.travis@nbt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Dr. Kasia Sieradzan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Howley</last_name>
      <phone>+44 (0) 20 7 829 7994</phone>
      <email>evelyn.howley@gosh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sophia Varadkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology &amp; Neurosurgery</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrs. Gohar Ghazumyan</last_name>
      <phone>+44 (0) 20 3 448 8632</phone>
      <email>Gohar.Ghazumyan@uclh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Andrew McEvoy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Chilcott</last_name>
      <phone>+44 (0) 186 523 2556</phone>
      <email>samanthachilcott@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Claire Hall</last_name>
      <phone>+44 (0) 186 523 2556</phone>
      <email>claire.hall1@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Arjune Sen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Parker</last_name>
      <phone>+44(0) 161 206 0531</phone>
      <email>Victoria.Parker@srft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Dr. Rajiv Mohanraj</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pene Fati</last_name>
      <phone>+44 (0) 114 271 3339</phone>
      <email>Pene.Fati@sth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Kamel Bouakline</last_name>
      <phone>+44 (0) 114 271 3339</phone>
      <email>kamel.bouakline@sth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Markus Reuber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>October 2, 2015</lastchanged_date>
  <firstreceived_date>January 5, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>V-COMPAS; Vagus Nerve Stimulation Clinical Outcomes;</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
